Related Experiment Video
Updated: Mar 28, 2026
08:51
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
9.6K
Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus
Vera Kemp1, Rob C Hoeben2, Diana J M van den Wollenberg3
1Department of Molecular Cell Biology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. v.kemp@lumc.nl.
Viruses
|December 30, 2015
Summary
Reoviruses show promise as oncolytic virotherapies, effectively targeting tumor cells. Enhancing their systemic delivery and understanding immune interactions are key to improving anti-cancer efficacy.
Area of Science:
- Virology
- Oncology
- Immunotherapy
Background:
- Reoviruses are non-enveloped viruses with double-stranded RNA genomes, naturally targeting tumor cells.
- Human reoviruses are well-tolerated in clinical trials for oncolytic virotherapy, with both intra-tumoral and systemic delivery showing promise.
- Current anti-cancer efficacy of reovirus monotherapy requires enhancement, particularly for systemic administration targeting primary tumors and metastases.
Purpose of the Study:
- To review reovirus/host-cell interactions and viral modification strategies.
- To focus on improving the anti-tumor efficacy of reoviruses in oncolytic virotherapy.
- To address challenges in systemic reovirus delivery, including the impact of the immune system.
Main Methods:
- Review of pre-clinical studies on reovirus delivery and efficacy.
- Analysis of reovirus/host-cell interactions.
- Discussion of viral modification techniques to enhance anti-tumor activity.
Main Results:
- Reoviruses demonstrate an inherent tropism for tumor cells, making them suitable for oncolytic virotherapy.
- Systemic delivery of reoviruses is a preferred route for targeting both primary tumors and metastases.
- Pre-clinical studies predominantly use immune-deficient models, limiting understanding of the immune system's role in tumor eradication.
Conclusions:
- Reovirus-based oncolytic virotherapy holds significant potential for cancer treatment.
- Further research is needed to optimize systemic delivery and overcome immune-related hurdles.
- Modifying reoviruses and understanding host interactions are crucial for maximizing anti-cancer efficacy.
Related Concept Videos
00:57Viral Recombination
25.6K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.6K
02:53Conservative Site-specific Recombination and Phase Variation
7.3K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
7.3K